Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia

Trial Details

NCT ID

NCT07321301

Phase

PHASE2

Sponsor

Daihong Liu

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Polymer-Lipid Nanoparticle-Mediated Delivery of CD19/CD20 Dual-Targeting InViVoCAR1920 mRNA for CAR-T Cell Immunotherapy

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Has voluntarily given informed consent, signed the informed consent form, and is willing and able to comply with the scheduled visits, study treatm…
• Patients with relapsed/refractory (R/R) B-cell lymphoma/leukemia confirmed by histopathology, cytogenetics, molecular biology, clinical judgment, m…
• Must meet the following criteria for R/R B-cell malignant tumors:
• (1) B-cell tumors include 3 categories:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.